CIBC Downgrades Aphria (NYSE:APHA) to Sector Underperform
CIBC lowered shares of Aphria (NYSE:APHA) from a neutral rating to a sector underperform rating in a report published on Friday morning, BenzingaRatingsTable reports.
A number of other brokerages have also commented on APHA. Clarus Securities initiated coverage on Aphria in a research note on Tuesday, April 16th. They set a buy rating and a $22.75 price target on the stock. Zacks Investment Research raised Garrett Motion from a sell rating to a hold rating in a research note on Friday, May 10th. Jefferies Financial Group reissued a buy rating and set a C$15.00 price target on shares of Aphria in a research note on Friday, May 24th. Finally, ValuEngine raised ZTE CORP/ADR from a hold rating to a buy rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. Aphria presently has a consensus rating of Hold and a consensus price target of $14.75.
Shares of APHA stock opened at $5.35 on Friday. The company’s 50-day moving average price is $6.60. Aphria has a 12 month low of $3.75 and a 12 month high of $16.86. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 38.21 and a beta of 3.14.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Further Reading: How mutual funds make money
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.